TissueCo, a tissue manufacturer facing margin compression versus competitors, should launch anti-viral tissues to improve profitability, driven by pandemic-driven demand and a forecasted 20% profit margin versus 10-15% for existing products.
Key Insights:
- Market sizing requires segmentation by use case (illness duration, frequency, ancillary needs) rather than simple per-capita consumption
- Product-level profitability analysis reveals that new category can pull up overall company margins through favorable mix
- Higher willingness-to-pay from germ-conscious consumers justifies premium positioning despite smaller addressable market
- Supply chain risk and competitive response represent key execution risks requiring sensitivity analysis